Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F17%3A10336208" target="_blank" >RIV/00216208:11160/17:10336208 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/17:00096876 RIV/00216208:11130/17:10336208 RIV/65269705:_____/17:00066935 RIV/00064203:_____/17:10336208

Výsledek na webu

<a href="http://link.springer.com/article/10.1007/s10198-015-0759-9" target="_blank" >http://link.springer.com/article/10.1007/s10198-015-0759-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10198-015-0759-9" target="_blank" >10.1007/s10198-015-0759-9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study

Popis výsledku v původním jazyce

Economic data pertaining to cystic fibrosis (CF), is limited in Europe generally, and completely lacking in Central and Eastern Europe. We performed an analysis of all direct costs associated with CF relative to key disease features and laboratory examinations. A retrospective prevalence-based cost-of-illness (COI) study was performed in a representative cohort of 242 CF patients in the Czech Republic, which represents about 65 % of all Czech CF patients. Medical records and invoices to health insurance companies for reference year 2010 were analyzed. The mean total health care costs were EUR 14,486 per patient, with the majority of the costs going towards medicinal products and devices (EUR 10,321). Medical procedures (EUR 2676) and inpatient care (EUR 1829) represented a much smaller percentage of costs. A generalized linear model showed that the strongest cost drivers, for all cost categories, were associated with patient age and lung disease severity (assessed using the FEV1 spirometric parameter), when compounded by chronic Pseudomonas aeruginosa airway infections. Specifically, maximum total costs are around the age 16 years; a FEV1 increase of 1 % point represented a cost decrease of: 0.9 % (medicinal products), 1.7 % (total costs), 2.8 % (procedures) and 7.0 % (inpatient care). COI analysis and regression modeling using the most recent data available can provide a better understanding of the overall economic CF burden. A comparison of our results with other methodologically similar studies demonstrates that although overall costs may differ, FEV1 can nonetheless be utilized as a generally transferrable indicator of the relative economic impact of CF.

Název v anglickém jazyce

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study

Popis výsledku anglicky

Economic data pertaining to cystic fibrosis (CF), is limited in Europe generally, and completely lacking in Central and Eastern Europe. We performed an analysis of all direct costs associated with CF relative to key disease features and laboratory examinations. A retrospective prevalence-based cost-of-illness (COI) study was performed in a representative cohort of 242 CF patients in the Czech Republic, which represents about 65 % of all Czech CF patients. Medical records and invoices to health insurance companies for reference year 2010 were analyzed. The mean total health care costs were EUR 14,486 per patient, with the majority of the costs going towards medicinal products and devices (EUR 10,321). Medical procedures (EUR 2676) and inpatient care (EUR 1829) represented a much smaller percentage of costs. A generalized linear model showed that the strongest cost drivers, for all cost categories, were associated with patient age and lung disease severity (assessed using the FEV1 spirometric parameter), when compounded by chronic Pseudomonas aeruginosa airway infections. Specifically, maximum total costs are around the age 16 years; a FEV1 increase of 1 % point represented a cost decrease of: 0.9 % (medicinal products), 1.7 % (total costs), 2.8 % (procedures) and 7.0 % (inpatient care). COI analysis and regression modeling using the most recent data available can provide a better understanding of the overall economic CF burden. A comparison of our results with other methodologically similar studies demonstrates that although overall costs may differ, FEV1 can nonetheless be utilized as a generally transferrable indicator of the relative economic impact of CF.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

<a href="/cs/project/7E13069" target="_blank" >7E13069: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Health Economics

ISSN

1618-7598

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

10

Strana od-do

73-82

Kód UT WoS článku

000392437100007

EID výsledku v databázi Scopus

2-s2.0-84953410327